Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 98 peer-reviewed journal articles Updated
Hematology

Dyskeratosis Congenita: A Patient Guide

At a Glance

Dyskeratosis congenita is an inherited telomere disorder that can cause bone marrow failure, lung scarring, and increased cancer risk. A bone marrow transplant may treat blood failure, but it does not remove the underlying problem, so lifelong specialist monitoring remains necessary.

How To Use This Guide
The information in this guide provides a starting point to help you understand Dyskeratosis Congenita. The recommendations outlined here are educational and are not a personal surveillance or emergency plan. Individual treatment decisions—especially regarding pediatric care, bone marrow transplantation, pregnancy, and emergency protocols—must be made in partnership with a medical team experienced in Telomere Biology Disorders.

Dyskeratosis Congenita is a complex, multi-system condition that belongs to a broader group of health issues known as Telomere Biology Disorders (TBD) [1]. At its core, the condition is caused by the inability of the body to maintain telomeres, which are the protective caps at the ends of our chromosomes that allow cells to divide and repair themselves safely [2]. When these caps become critically short, the cells can no longer regenerate, leading to a “cellular exhaustion” that primarily affects tissues requiring rapid and constant renewal, such as the bone marrow, skin, and the linings of the lungs and digestive tract [3][4].

The way this disorder appears can vary dramatically from one person to another, even within the same family. Traditionally, it was identified by a “classic triad” of physical signs—changes in skin pigmentation, nail growth, and white patches in the mouth—but we now understand that many patients may never show these outward signs [5][6]. Instead, the condition often presents as a spectrum. Some individuals face severe complications in early childhood, while others may not be diagnosed until adulthood when they develop unexplained lung scarring or blood disorders [7][8]. This variability is partly due to the different genetic mutations involved and a phenomenon where telomeres can be inherited at a shorter length with each passing generation, a concept known as genetic anticipation [9].

Living with Dyskeratosis Congenita requires a focus on three primary systemic risks: the failure of the bone marrow to produce enough blood cells, the development of scarring in the lungs known as pulmonary fibrosis, and a significantly higher risk for certain cancers, particularly squamous cell carcinomas of the head, neck, and skin [1][10]. While a bone marrow transplant can be a life-saving, potentially curative treatment for the blood-related issues, it is crucial to recognize that it is not a complete cure for the underlying disorder [11]. Because the telomere defect remains in the rest of the body’s cells, the risks to other organs and the potential for cancer persist, making lifelong, specialized surveillance the cornerstone of effective management [12][13].

Despite the challenges of managing such a rare and complex condition, understanding the biology of the disorder empowers you to advocate for the most appropriate care. Modern medicine continues to refine specialized protocols for treatments and more precise screening methods to catch complications at their earliest, most treatable stages [14]. By working with a dedicated team of specialists who understand the unique needs of patients with Telomere Biology Disorders, you can build a proactive plan focused on preserving organ function and maintaining the best possible quality of life [15][16].

In this guide

6 chapters

01

Understanding Dyskeratosis Congenita and Telomere Biology

Learn how dyskeratosis congenita affects telomeres, bone marrow, skin, lungs, and liver, and why specialized multisystem care matters for patients and families.

02

Symptoms, Warning Signs, and Systemic Complications

Learn the classic signs of dyskeratosis congenita, major bone marrow, lung, and liver complications, and when symptoms require urgent or emergency care.

03

The Science of Diagnosis: Genes and Telomeres

Learn how dyskeratosis congenita is diagnosed through genetic testing, Flow-FISH telomere length, inheritance patterns, and tests that rule out Fanconi anemia.

04

Severe Subtypes and the Spectrum of Disease

Learn how dyskeratosis congenita ranges from severe childhood syndromes to adult-onset disease, including eye, lung, liver, blood, and family genetic risk.

05

Treatment Options for Bone Marrow Failure

Learn how dyskeratosis congenita bone marrow failure is treated, including supportive care, androgen therapy, donor screening, and transplant risks.

06

Protecting Your Future: Long-Term Monitoring and Cancer Surveillance

Learn how people with dyskeratosis congenita can plan lifelong monitoring, cancer surveillance, organ testing, surgery precautions, and support for scanxiety.

Common questions in this guide

What is dyskeratosis congenita, and what parts of the body can it affect?
Dyskeratosis congenita is a rare inherited condition in which cells cannot maintain telomeres, the protective ends of chromosomes. It can affect the bone marrow, lungs, skin, mouth, digestive tract, and other organs.
What are the main health problems caused by dyskeratosis congenita?
The major concerns are bone marrow failure, lung scarring called pulmonary fibrosis, and an increased risk of certain cancers. Squamous cell cancers of the head, neck, and skin are particular concerns.
Can someone have dyskeratosis congenita without the classic skin, nail, and mouth findings?
Yes. Some people never develop the typical skin pigmentation changes, nail abnormalities, or white patches in the mouth. Others may not be diagnosed until adulthood after unexplained lung or blood problems appear.
Does a bone marrow transplant cure dyskeratosis congenita?
No. A bone marrow transplant can treat severe blood-cell production problems and may be life-saving, but it does not correct the underlying telomere problem in the rest of the body. Risks affecting the lungs, other organs, and cancer development can continue.
Why does dyskeratosis congenita require lifelong specialist monitoring?
The underlying telomere problem can continue to affect multiple organs even after treatment for bone marrow failure. Lifelong monitoring helps the medical team look for blood, lung, liver, and cancer-related complications as early as possible.
How can genetic anticipation affect family testing for dyskeratosis congenita?
Genetic anticipation means that shorter telomeres and more severe health problems may appear in younger generations of a family. A genetics team can help determine which relatives should be evaluated and how to plan testing for children and other family members.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the broad spectrum of Telomere Biology Disorders, how does my (or my child's) specific presentation help us determine which specialists we need to see first?
  2. 2.Can we review the goals of care for both the blood-related symptoms and the long-term health of other organs like the lungs and liver?
  3. 3.How does our clinic coordinate with a specialized center of excellence to ensure we are following the most current management protocols?
  4. 4.What is the plan for screening our family members, and how does 'genetic anticipation' affect the testing of younger generations?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Dyskeratosis congenita and telomere biology disorders.

    Savage SA

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):637-648 doi:10.1182/hematology.2022000394.

    PMID: 36485133
  2. 2

    Beginning at the ends: telomeres and human disease.

    Savage SA

    F1000Research 2018; (7()) doi:10.12688/f1000research.14068.1.

    PMID: 29770205
  3. 3

    Loss of Ten1 in mice induces telomere shortening and models human dyskeratosis congenita.

    Sanz-Moreno A, Becker L, Xie K, et al.

    Science advances 2025; (11(15)):eadp8093 doi:10.1126/sciadv.adp8093.

    PMID: 40215293
  4. 4

    Recent advances in understanding telomere diseases.

    Carvalho VS, Gomes WR, Calado RT

    Faculty reviews 2022; (11()):31 doi:10.12703/r/11-31.

    PMID: 36311538
  5. 5

    Two Cases of Dyskeratosis Congenita with Clinically Distinct Presentations, Seen in National University Hospital, Singapore.

    Juay L, Chandran NS

    Skin appendage disorders 2022; (8(1)):53-56 doi:10.1159/000518299.

    PMID: 35111818
  6. 6

    [Dyskeratosis congenita combined with myeloproliferative disorder and trilineage cytopenia].

    Peng YL, Qian XT, Tian YQ, et al.

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2025; (48(6)):540-547 doi:10.3760/cma.j.cn112147-20241010-00593.

    PMID: 40491143
  7. 7

    Disease progression and clinical outcomes in telomere biology disorders.

    Niewisch MR, Giri N, McReynolds LJ, et al.

    Blood 2022; (139(12)):1807-1819 doi:10.1182/blood.2021013523.

    PMID: 34852175
  8. 8

    Clinical manifestations of telomere biology disorders in adults.

    Niewisch MR, Beier F, Savage SA

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):563-572 doi:10.1182/hematology.2023000490.

    PMID: 38066848
  9. 9

    A novel homozygous RTEL1 variant in a consanguineous Lebanese family: phenotypic heterogeneity and disease anticipation.

    Gutierrez-Rodrigues F, Masri N, Chouery E, et al.

    Human genetics 2019; (138(11-12)):1323-1330 doi:10.1007/s00439-019-02076-8.

    PMID: 31677132
  10. 10

    Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.

    Alter BP, Giri N, Savage SA, Rosenberg PS

    Haematologica 2018; (103(1)):30-39 doi:10.3324/haematol.2017.178111.

    PMID: 29051281
  11. 11

    Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.

    Fioredda F, Iacobelli S, Korthof ET, et al.

    British journal of haematology 2018; (183(1)):110-118 doi:10.1111/bjh.15495.

    PMID: 29984823
  12. 12

    Stem cell transplantation and gene therapy for telomere biology disorders: Historical perspective, current approaches, and emerging strategies.

    Koo J, Reed HD, Myers KC, Agarwal S

    Seminars in hematology 2025; (62(6)):493-502 doi:10.1053/j.seminhematol.2026.03.001.

    PMID: 41916788
  13. 13

    Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

    Hudda Z, Myers KC

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):141-148 doi:10.1182/hematology.2023000471.

    PMID: 38066882
  14. 14

    Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.

    Dimitrov M, Merkle S, Cao Q, et al.

    Transplantation and cellular therapy 2024; (30(10)):1005.e1-1005.e17 doi:10.1016/j.jtct.2024.07.007.

    PMID: 39002862
  15. 15

    TeloNet is born: why all specialities need to be aware of telomere biology disorders.

    Longhurst HJ, Paxton JK, Tummala H, et al.

    Frontiers in medicine 2026; (13()):1780232 doi:10.3389/fmed.2026.1780232.

    PMID: 42110436
  16. 16

    The wide-ranging clinical implications of the short telomere syndromes.

    Barbaro PM, Ziegler DS, Reddel RR

    Internal medicine journal 2016; (46(4)):393-403 doi:10.1111/imj.12868.

    PMID: 26247919

This guide is for informational purposes only and does not constitute medical advice or a personal surveillance or emergency plan. Discuss treatment, transplantation, pregnancy, and family screening with a team experienced in telomere biology disorders.

Get notified when new evidence is published on Dyskeratosis congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.